Plasma levels of interleukin-6 and antidepressant response to Paroxetine in Chinese depressive patients
Plasma levels of interleukin-6 and antidepressant response to Paroxetine in Chinese depressive patients
复制标题
中国抑郁症患者血浆白细胞介素6水平和帕罗西汀抗抑郁反应
DOI：
10.1016/j.psychres.2021.113723
复制
发表时间：
2021-02-02
影响因子：
11.3
通讯作者：
Tian, Liantian
中科院分区：
文献类型：
--
作者：
Dong, Zaiquan;Kuang, Weihong;Tian, Liantian
本研究旨在探讨白细胞介素 - 6（IL - 6）血浆水平与重度抑郁症（MDD）患者选择性5 - 羟色胺再摄取抑制剂治疗结果之间的相关性。共纳入104名患者（33名男性和71名女性），年龄在18至72岁之间。在治疗开始前（基线）以及口服帕罗西汀治疗8周后采集外周血样本。采用汉密尔顿抑郁量表（HAMD） - 17评估帕罗西汀的疗效。发现对治疗有反应的患者基线血浆IL - 6水平显著低于无反应者。HAMD - 17减分率与基线IL - 6水平呈负相关。此外，还研究了患者HAMD - 17减分率与其他因素（如IL - 6水平、性别、年龄和体重指数）之间的关联。基线IL - 6是唯一对第8周HAMD - 17减分率有显著影响的因素。这些结果表明，血浆IL - 6水平可能是预测个体MDD患者对帕罗西汀可能的治疗反应的一个有前景的生物学标志物。
This study aimed to investigate the correlation between interleukin-6 (IL-6) plasma levels and treatment outcomes of selective serotonin reuptake inhibitors in patients with major depressive disorder (MDD). A total of 104 patients (33 males and 71 females), aged 18 to 72 years, were enrolled. Peripheral blood samples were collected before treatment initiation (baseline) and eight weeks after oral paroxetine treatment. The Hamilton Depression Rating Scale (HAMD)-17 was used to evaluate the efficacy of paroxetine. Baseline plasma IL-6 levels were found to be significantly lower in patients who responded to treatment than in non-responders. A negative correlation was found between the HAMD-17 reduction rate and baseline IL-6 levels. Furthermore, associations were examined between HAMD-17 reduction rate in patients and other factors, such as IL-6 levels, sex, age, and body mass index. Baseline IL-6 was the only factor showing a significant impact on the reduction rate of HAMD-17 at week 8. These results suggest that plasma IL-6 level may be a promising biological marker for predicting the likely treatment response to paroxetine in individual patients with MDD.